TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

NCT ID: NCT03388268

Last Updated: 2021-07-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-29
• Study Completion Date: 2021-01-31

Brief Summary

The purpose of this study is to determine the risks and benefits of antibiotic treatment for Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.

Currently, healthcare facilities use a wide variety of tests and strategies for identifying patients with CDI; both EIA and NAAT are widely used. There is no clear gold standard for identifying CDI. At WUSM and BJH, patients are only treated for CDI if they have a positive EIA. However, at many other healthcare facilities, the standard of care is to treat for CDI if the patient is NAAT positive. Some patients who are NAAT-positive may not have true CDI; while this treatment is standard of care at many facilities, the risk and benefits of treating these patients for CDI is unknown.

We propose to perform a double blinded, randomized controlled non-inferiority trial of antimicrobial of patients who are EIA negative, NAAT positive to determine the risks and benefits of CDI treatment in this population.

Detailed Description

Study Purpose:

The purpose of this study is to determine the risks and benefits of antibiotic treatment for Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.

Background:

Clostridium difficile infection (CDI) is the most common cause of healthcare-associated diarrhea. There is no gold standard diagnostic test for (CDI). Commercially available assays detect C. difficile or its toxins in stool. Nucleic acid amplification tests (NAAT) are much more sensitive than toxin enzyme immunoassays (EIA). However, clinical correlation is needed to determine who has CDI. Most US clinical microbiology laboratories have adopted NAATs for C. difficile under the presumption the enhanced analytical sensitivity was beneficial. Although some patients with NAAT-positive/toxin-negative stool have CDI and a false-negative toxin EIA, subsequent studies indicate most patients with NAAT-positive / toxin-negative stool do not have CDI. Rather, they are asymptomatic C. difficile carriers who have diarrhea for other reasons. Most of these studies also have limitations and considerable controversy remains for whether NAATs or toxin EIAs should be used when CDI is suspected.

Treatment of asymptomatic C. difficile carriers is not beneficial, and may result in harm. At hospitals that utilize NAATs, most patients with NAAT-positive / toxin-negative stool receive treatment for CDI. The most common treatments for CDI, metronidazole and oral vancomycin, are highly disruptive of the intestinal microbiome. These antimicrobials create selective pressures that promote the acquisition and proliferation of antimicrobial resistance and multidrug resistant organisms (MDRO), including public health threats such as MDRO Enterobacteriaceae like carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL) producing organisms, vancomycin-resistant Enterococcus (VRE), and the latest emerging threat Candida auris. This leads to MDRO infections and MDRO spread to others. Paradoxically, unnecessary treatment for CDI may increase risk for CDI once treatment is stopped contributing to CDI-related adverse events and C. difficile spread to others. Unnecessary CDI treatment potentially harms both that patient and other people. Whether the benefit of treating patients with NAAT-positive/toxin-negative stool that are missed cases of CDI outweighs the risk of treating patients with NAAT-positive/toxin-negative stool that are asymptomatic C. difficile carriers remains unknown.

This study is a double-blinded randomized controlled trial of CDI treatment for patients with NAAT-positive / toxin-negative stool. Such a trial is necessary to understand the risk-benefit of treating these patients for CDI. Patients with NAAT-positive / toxin-negative stool who consent to participate will be randomized to 10 days of oral vancomycin or placebo. Stool and environmental specimens will be obtained at regular time points and interrogated with culturomic and metagenomic methods. Patients will be followed until eight weeks after discontinuation of study drug. These data and specimens will be used to determine the impact of oral vancomycin versus placebo on the microbiome, C. difficile and MDRO colonization, environmental contamination, duration of diarrhea, CDI-related adverse events, and death.

Specific aims and hypotheses:

Specific Aim 1: Determine if there are differences in microbiome disruption and acquisition / persistence of C. difficile and other MDRO carriage in stool among patients with NAAT-positive / toxin-negative stool who are randomized to a 10-day course of oral vancomycin versus placebo.

Hypotheses: Study participants who receive oral vancomycin will have greater disruption of the taxonomic and functional metabolic profiles of the fecal microbiome, increases in antimicrobial resistance genes, acquire more MDRO, and will have greater persistence and abundance of MDRO in stool compared to participants who receive placebo. Participants who receive oral vancomycin will not have detectable C. difficile in stool after completion of study drug, but will be more likely to have C. difficile in stool at week 8 after completion of study drug compared to participants who receive placebo.

Specific Aim 2: Determine if there are differences in C. difficile and other MDRO environmental contamination between treatment groups.

Hypothesis: Study participants who receive oral vancomycin will have less environmental C. difficile contamination but more MDRO contamination compared to participants who receive placebo while receiving study drug. After study drug is completed, those who receive oral vancomycin will have more environmental contamination due to both C. difficile and other MDROs.

Specific Aim 3: Determine if there are differences in CDI-related outcomes between groups.

Hypothesis: There will be no difference in time to resolution of diarrhea or CDI-related outcomes between treatment groups.

Conditions

Clostridium Difficile Infection; Diarrhea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

Oral vancomycin

125mg of oral vancomycin four times per day

Group Type: ACTIVE_COMPARATOR

Oral Vancomycin

Intervention Type: DRUG

Oral vancomycin 125mg 4 times per day

Toxin enzyme immunoassay

Intervention Type: DEVICE

EIA assay: Wampole/Tech Lab Tox A/B II

Nuceleic acid amplification test

Intervention Type: DEVICE

NAAT: Xpert C. difficile, Cepheid

Placebo

Placebo four times per day

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Sugar liquid manufactured to mimic oral vancomycin 125mg

Toxin enzyme immunoassay

Intervention Type: DEVICE

EIA assay: Wampole/Tech Lab Tox A/B II

Nuceleic acid amplification test

Intervention Type: DEVICE

NAAT: Xpert C. difficile, Cepheid

Interventions

Oral Vancomycin

Oral vancomycin 125mg 4 times per day

Intervention Type: DRUG

Placebo

Sugar liquid manufactured to mimic oral vancomycin 125mg

Intervention Type: DRUG

Toxin enzyme immunoassay

EIA assay: Wampole/Tech Lab Tox A/B II

Intervention Type: DEVICE

Nuceleic acid amplification test

NAAT: Xpert C. difficile, Cepheid

Intervention Type: DEVICE

Other Intervention Names

Vancocin

Eligibility Criteria

Inclusion Criteria

• Stool submitted to the BJH microbiology laboratory for C. difficile testing that tests negative for C. difficile toxins (C. difficile Tox A/B II, Alere, Waltham, MA) as part of routine clinical care and positive by NAAT (Xpert C. difficile, Cepheid, Sunnyvale, CA)
• Clinically significant diarrhea (≥3 diarrheal bowel movements per day or ≥1 diarrheal bowel movement plus abdominal pain)
• ≥18 years of age.

Exclusion Criteria

• The presence of a condition associated with persistent / prolonged / recurrent diarrhea, including, but not limited to:
• Upcoming chemotherapy
• Previous or upcoming bone marrow/hematopoietic stem cell transplant,
• Leukemia: new, not in remission, or receiving chemotherapy
• Inflammatory bowel disease
• Crohn's disease
• Ulcerative colitis
• Microscopic colitis
• Previous total colectomy
• Previous partial colectomy without return to formed bowel movement or previous resection of colon
• Colostomy or ileostomy
• Unable to follow study procedures
• Not expected to survive until study follow-up is complete
• Allergy or intolerance to oral vancomycin
• A history of CDI in the past 3 months
• Alternate infectious etiology for diarrhea
• Receipt of CDI antibiotic treatment (excluding empiric treatment given while pending EIA results)
• Does not provide consent will exclude a patient from participating in the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Erik Dubberke, MD, MSPH

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Washington University

St Louis, Missouri, United States

Countries

United States

References

Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, Seiler S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients. mSphere. 2021 Jan 13;6(1):e00936-20. doi: 10.1128/mSphere.00936-20.

Reference Type: DERIVED

PMID: 33441409 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

201708055

Identifier Type: -

Identifier Source: org_study_id